Asahi Kasei’s FO-MD System Trialed at Peptistar for Faster API Production
Event summary
- Asahi Kasei’s forward osmosis–membrane distillation (FO-MD) system installed at Peptistar’s API manufacturing facility for trial production.
- System reduces freeze-drying time by concentrating solutions without heat or pressure, addressing challenges in next-generation therapeutic APIs.
- Trial involves batches up to 100L, with evaluation toward GMP-compliant production.
- Asahi Kasei positions Life Science as a Growth Potential business in its medium-term management plan.
The big picture
Asahi Kasei’s FO-MD system addresses a critical bottleneck in API manufacturing, particularly for heat-sensitive biologics like peptides and oligonucleotides. The trial at Peptistar reflects broader industry shifts toward more efficient, scalable production methods for complex therapeutics. As demand grows for next-generation APIs, the success of this technology could position Asahi Kasei as a key enabler in pharmaceutical manufacturing innovation.
What we're watching
- Commercialization Prospects
- Whether Asahi Kasei can successfully scale the FO-MD system for broader commercial use in API manufacturing.
- GMP Compliance
- The pace at which Peptistar achieves GMP certification for the novel system, validating its regulatory viability.
- Industry Adoption
- How quickly other CDMOs adopt FO-MD technology to address challenges in next-generation therapeutic production.
Related topics